Darolutamide Gets Priority Review for Non-Metastatic Castration-Resistant Prostate Cancer
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for darolutamide (Bayer and Orion), an investigational treatment for non-metastatic castration-resistant prostate cancer (nmCRPC).